ASI’s Riverview facility to manufacture Ponatinib API
The FDA approved the drug on December 14, 2012 for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
The settlement also resolves similar open civil investigations against Walgreens Jupiter Distribution Center and six Walgreens retail pharmacies (together known as "Registrants") in Florida, Colorado, Michigan and Eastern